Oncotarget

Reviews:

Cold atmospheric plasma, a novel promising anti-cancer treatment modality

Dayun Yan _, Jonathan H. Sherman and Michael Keidar

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:15977-15995. https://doi.org/10.18632/oncotarget.13304

Metrics: PDF 5978 views  |   HTML 12549 views  |   ?  


Abstract

Dayun Yan1, Jonathan H. Sherman2 and Michael Keidar1

1 Department of Mechanical and Aerospace Engineering, The George Washington University, NW, Washington, DC, USA

2 Neurological Surgery, The George Washington University, NW, Washington, DC, USA

Correspondence to:

Dayun Yan, email:

Michael Keidar, email:

Keywords: cold plasma, cancer treatment, reactive species, selectivity

Received: September 14, 2016 Accepted: October 29, 2016 Published: November 11, 2016

Abstract

Over the past decade, cold atmospheric plasma (CAP), a near room temperature ionized gas has shown its promising application in cancer therapy. Two CAP devices, namely dielectric barrier discharge and plasma jet, show significantly anti-cancer capacity over dozens of cancer cell lines in vitro and several subcutaneous xenograft tumors in vivo. In contrast to conventional anti-cancer approaches and drugs, CAP is a selective anti-cancer treatment modality. Thus far establishing the chemical and molecular mechanism of the anti-cancer capacity of CAP is far from complete. In this review, we provide a comprehensive introduction of the basics of CAP, state of the art research in this field, the primary challenges, and future directions to cancer biologists.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13304